Dong-Gun Kim

Chief Executive Officer

Dong-Gun (DG) Kim became CEO of Immunomic Therapeutics in 2023 after serving on the Company’s Board and as CEO of HLB from 2020.  Before joining HLB, Mr. Kim spent over 30 years as a specialist in M&A, corporate finance and investment management.  He began his career at the law firm of Latham & Watkins, where he spent seven years as a corporate finance and M&A attorney.  He then worked for ten years on Wall Street as an M&A investment banker, including as head of telecom M&A for Deutsche Bank in New York, advising on $100 billion of transactions.  Mr. Kim moved to Korea in 2005 to head up Eugene Asset Management’s alternative investment operations, raising and managing KRW 3 trillion (approximately US$3 billion) of funding in private equity, distressed debt and other alternative investments.  In 2012, he joined E-Land Group, a Korean conglomerate operating in fashion and retail, and served as Group CFO for three years.  He then spent another three years as CFO and Deputy CIO of Allied Inventors Fund, a specialty private equity fund based in Seattle investing in IP assets with over $600 million under management.  Mr. Kim has an A.B. in Physics from Harvard College and a J.D. from Harvard Law School.